Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility

by Zacks Equity Research

OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.

    Horizon Therapeutics (HZNP) Down 1.8% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

    by Zacks Equity Research

    Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

    Horizon Therapeutics (HZNP) Misses Q1 Earnings Estimates

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    John Blank headshot

    Will Central Banks Start to Care About Fundamentals?

    by John Blank

    Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.

    Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    BMY or HZNP: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    BMY vs. HZNP: Which Stock Is the Better Value Option?

    Why Is Horizon Therapeutics (HZNP) Down 8.1% Since Last Earnings Report?

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Immunovant (IMVT) Gains on a Potential Buyout by Roivant

    by Zacks Equity Research

    Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.

    Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat

    by Zacks Equity Research

    Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

    Company News for Feb 25, 2021

    by Zacks Equity Research

    Companies In The News Are: VCEL, LNG, HZNP, PRAH

    Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls

    by Zacks Equity Research

    Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.

    Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Horizon Therapeutics (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

    Horizon (HZNP) Provides Preliminary 2020 Financial Results

    by Zacks Equity Research

    Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

    New Strong Sell Stocks for January 6th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

    Horizon Therapeutics (HZNP) Down 6.7% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.

    Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology

    by Zacks Equity Research

    Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.

    Is Horizon Therapeutics (HZNP) a Worthy Stock Now?

    by Zacks Equity Research

    Let's see if Horizon Therapeutics (HZNP) stock is a good choice for value-oriented investors right now from multiple angles.

    Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?

    by Zacks Equity Research

    Sector ETF report for XPH

    Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses

    by Zacks Equity Research

    Allogene (ALLO) reports no revenues for the third quarter of 2020.

    Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales

    by Zacks Equity Research

    Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.